Last reviewed · How we verify
Gelatin 500 mL
Gelatin 500 mL, marketed by Hopital Foch, is a currently available pharmaceutical product with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a competitive advantage until expiry. The lack of detailed revenue and clinical trial data poses a significant risk in assessing its market performance and potential threats from competitors.
At a glance
| Generic name | Gelatin 500 mL |
|---|---|
| Sponsor | Hopital Foch |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma (PHASE3)
- Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus (PHASE3)
- Tranexamic Acid During Upper GI Endoscopic Resection Procedures (PHASE4)
- Effectiveness of Vitamin E and Hydrogen-Rich Water on Radiation Therapy-Induced Adverse In Patients With Rectal Cancer (PHASE3)
- To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects. (PHASE1)
- Whether a Minimal Volume Could Predict Fluid Responsiveness Using Thermodilution by PAC in Septic Shock Patients (NA)
- Goal Directed Fluid Management , Pvi (NA)
- SRAE With Embospheres for Hemorrhoids. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gelatin 500 mL CI brief — competitive landscape report
- Gelatin 500 mL updates RSS · CI watch RSS
- Hopital Foch portfolio CI